Two most widely applied immunotherapies in BLCA are Bacillus Calmette–Guerin (BCG) intravesical instillation and anti‐PD‐1/PD‐L1 immune checkpoint blockade.29 Here, PDCD1 is linked to bladder transitional cell carcinoma.